Van Eck Associates Corp Charles River Laboratories International, Inc. Transaction History

Van Eck Associates Corp

$64.4 Billion
Q1 2024

A detailed history of Van Eck Associates Corp transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 55,637 shares of CRL stock, worth $11.5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

55,637

Previous 57,679 3.54%

Holding current value

$11.5 Million

Previous $13.6 Million 10.55%

% of portfolio

0.02%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	SELL	$203.52 - $273.43 $415,587 - $558,344	-2,042 Reduced 3.54%	55,637 $15.1 Million
Q4 2023 Feb 05, 2024	SELL	$164.52 - $238.84 $891,369 - $1.29 Million	-5,418 Reduced 8.59%	57,679 $13.6 Million
Q3 2023 Nov 08, 2023	BUY	$194.44 - $217.61 $1.45 Million - $1.62 Million	7,461 Added 13.41%	63,097 $12.4 Million
Q2 2023 Aug 03, 2023	BUY	$183.71 - $210.25 $438,515 - $501,866	2,387 Added 4.48%	55,636 $11.7 Million
Q1 2023 May 03, 2023	SELL	$191.89 - $259.92 $1.53 Million - $2.07 Million	-7,950 Reduced 12.99%	53,249 $10.7 Million

Q4 2022 Feb 08, 2023	BUY	$197.11 - $250.07 $3.13 Million - $3.97 Million	15,893 Added 35.08%	61,199 $13.3 Million
Q3 2022 Oct 27, 2022	SELL	$182.44 - $250.54 $2.88 Million - $3.95 Million	-15,778 Reduced 25.83%	45,306 $8.92 Million
Q2 2022 Aug 03, 2022	BUY	$204.13 - $302.4 $878,779 - $1.3 Million	4,305 Added 7.58%	61,084 $13.1 Million
Q1 2022 May 10, 2022	BUY	$255.51 - $362.11 $64,644 - $91,613	253 Added 0.45%	56,779 $16.1 Million
Q4 2021 Jan 26, 2022	SELL	$351.38 - $448.68 $1.43 Million - $1.83 Million	-4,076 Reduced 6.73%	56,526 $21.3 Million
Q3 2021 Nov 03, 2021	SELL	$372.64 - $458.3 $4.25 Million - $5.22 Million	-11,399 Reduced 15.83%	60,602 $25 Million
Q2 2021 Aug 10, 2021	BUY	$294.17 - $371.65 $1.69 Million - $2.14 Million	5,757 Added 8.69%	72,001 $26.6 Million
Q1 2021 May 13, 2021	SELL	$249.67 - $299.48 $1.31 Million - $1.57 Million	-5,255 Reduced 7.35%	66,244 $19.2 Million
Q4 2020 Feb 09, 2021	BUY	$222.0 - $252.62 $1.54 Million - $1.75 Million	6,915 Added 10.71%	71,499 $17.9 Million
Q3 2020 Nov 12, 2020	SELL	$175.56 - $226.45 $2.37 Million - $3.06 Million	-13,522 Reduced 17.31%	64,584 $14.6 Million
Q2 2020 Aug 10, 2020	BUY	$118.84 - $189.72 $2.09 Million - $3.33 Million	17,569 Added 29.02%	78,106 $13.6 Million
Q1 2020 May 12, 2020	SELL	$98.9 - $178.34 $1.53 Million - $2.76 Million	-15,455 Reduced 20.34%	60,537 $7.64 Million
Q4 2019 Feb 13, 2020	BUY	$126.05 - $152.76 $128,066 - $155,204	1,016 Added 1.36%	75,992 $11.6 Million
Q3 2019 Nov 08, 2019	BUY	$125.07 - $143.67 $226,876 - $260,617	1,814 Added 2.48%	74,976 $9.93 Million
Q2 2019 Aug 07, 2019	SELL	$123.4 - $148.55 $1.7 Million - $2.05 Million	-13,803 Reduced 15.87%	73,162 $10.4 Million
Q1 2019 May 13, 2019	SELL	$104.82 - $146.73 $1.46 Million - $2.05 Million	-13,974 Reduced 13.84%	86,965 $12.6 Million
Q4 2018 Feb 12, 2019	BUY	$105.09 - $137.23 $712,720 - $930,693	6,782 Added 7.2%	100,939 $11.4 Million
Q3 2018 Nov 13, 2018	BUY	$112.11 - $134.54 $53,924 - $64,713	481 Added 0.51%	94,157 $12.7 Million
Q2 2018 Aug 13, 2018	BUY	$102.37 - $117.25 $1.36 Million - $1.56 Million	13,291 Added 16.53%	93,676 $10.5 Million
Q1 2018 May 11, 2018	SELL	$98.19 - $115.2 $1.88 Million - $2.21 Million	-19,168 Reduced 19.25%	80,385 $8.58 Million
Q4 2017 Feb 12, 2018	SELL	$100.43 - $118.09 $5.42 Million - $6.37 Million	-53,924 Reduced 35.13%	99,553 $10.9 Million
Q3 2017 Nov 09, 2017	BUY	$96.72 - $109.26 $502,460 - $567,605	5,195 Added 3.5%	153,477 $16.6 Million
Q2 2017 Aug 11, 2017	BUY	N/A	148,282	148,282 $15 Million

Others Institutions Holding CRL

# of Institutions

727

Shares Held

51.3M

Call Options Held

183K

Put Options Held

346K

View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $10.5B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

More about CRL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Charles River Laboratories International, Inc. Transaction History